vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and CRA INTERNATIONAL, INC. (CRAI). Click either name above to swap in a different company.
CRA INTERNATIONAL, INC. is the larger business by last-quarter revenue ($197.0M vs $183.1M, roughly 1.1× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 6.7%, a 6.6% gap on every dollar of revenue. On growth, CRA INTERNATIONAL, INC. posted the faster year-over-year revenue change (11.6% vs -1.8%). Over the past eight quarters, CRA INTERNATIONAL, INC.'s revenue compounded faster (7.1% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
CRA INTERNATIONAL, INC.CRAIEarnings & Financial Report
CRA International, Inc. is a global consulting firm headquartered in Boston. The firm provides expert testimony and litigation support, strategic advice, and analysis to law firms, corporations, accounting firms, and governments.
AMPH vs CRAI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $197.0M |
| Net Profit | $24.4M | $13.2M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 10.5% |
| Net Margin | 13.3% | 6.7% |
| Revenue YoY | -1.8% | 11.6% |
| Net Profit YoY | -35.7% | -12.0% |
| EPS (diluted) | $0.51 | $1.99 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $197.0M | ||
| Q3 25 | $191.8M | $185.9M | ||
| Q2 25 | $174.4M | $186.9M | ||
| Q1 25 | $170.5M | $181.9M | ||
| Q4 24 | $186.5M | $176.4M | ||
| Q3 24 | $191.2M | $167.7M | ||
| Q2 24 | $182.4M | $171.4M | ||
| Q1 24 | $171.8M | $171.8M |
| Q4 25 | $24.4M | $13.2M | ||
| Q3 25 | $17.4M | $11.5M | ||
| Q2 25 | $31.0M | $12.1M | ||
| Q1 25 | $25.3M | $18.0M | ||
| Q4 24 | $38.0M | $15.0M | ||
| Q3 24 | $40.4M | $11.4M | ||
| Q2 24 | $37.9M | $6.5M | ||
| Q1 24 | $43.2M | $13.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 10.5% | ||
| Q3 25 | 13.2% | 9.3% | ||
| Q2 25 | 24.2% | 10.6% | ||
| Q1 25 | 21.9% | 14.0% | ||
| Q4 24 | 24.2% | 12.2% | ||
| Q3 24 | 29.8% | 11.0% | ||
| Q2 24 | 30.3% | 6.6% | ||
| Q1 24 | 27.9% | 11.4% |
| Q4 25 | 13.3% | 6.7% | ||
| Q3 25 | 9.0% | 6.2% | ||
| Q2 25 | 17.8% | 6.5% | ||
| Q1 25 | 14.8% | 9.9% | ||
| Q4 24 | 20.4% | 8.5% | ||
| Q3 24 | 21.1% | 6.8% | ||
| Q2 24 | 20.8% | 3.8% | ||
| Q1 24 | 25.1% | 8.0% |
| Q4 25 | $0.51 | $1.99 | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.64 | — | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.73 | — | ||
| Q1 24 | $0.81 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $18.2M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $213.6M |
| Total Assets | $1.6B | $628.9M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $18.2M | ||
| Q3 25 | $276.2M | $22.5M | ||
| Q2 25 | $231.8M | $19.4M | ||
| Q1 25 | $236.9M | $25.6M | ||
| Q4 24 | $221.6M | $26.7M | ||
| Q3 24 | $250.5M | $24.5M | ||
| Q2 24 | $217.8M | $24.6M | ||
| Q1 24 | $289.6M | $37.1M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $213.6M | ||
| Q3 25 | $776.7M | $201.7M | ||
| Q2 25 | $757.5M | $197.0M | ||
| Q1 25 | $751.3M | $227.3M | ||
| Q4 24 | $732.3M | $212.1M | ||
| Q3 24 | $727.7M | $204.5M | ||
| Q2 24 | $713.3M | $191.7M | ||
| Q1 24 | $672.4M | $211.8M |
| Q4 25 | $1.6B | $628.9M | ||
| Q3 25 | $1.7B | $629.0M | ||
| Q2 25 | $1.6B | $606.8M | ||
| Q1 25 | $1.6B | $590.4M | ||
| Q4 24 | $1.6B | $571.4M | ||
| Q3 24 | $1.5B | $582.3M | ||
| Q2 24 | $1.5B | $546.0M | ||
| Q1 24 | $1.6B | $552.5M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $22.4M |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | 1.70× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $22.4M | ||
| Q3 25 | $52.6M | $36.5M | ||
| Q2 25 | $35.6M | $5.9M | ||
| Q1 25 | $35.1M | $-80.0M | ||
| Q4 24 | $29.0M | $79.4M | ||
| Q3 24 | $60.0M | $31.6M | ||
| Q2 24 | $69.1M | $1.8M | ||
| Q1 24 | $55.3M | $-63.1M |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | $35.9M | ||
| Q2 25 | $25.0M | $4.7M | ||
| Q1 25 | $24.4M | $-81.0M | ||
| Q4 24 | $16.6M | $68.8M | ||
| Q3 24 | $46.2M | $28.6M | ||
| Q2 24 | $63.1M | $-509.0K | ||
| Q1 24 | $46.5M | $-63.8M |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | 19.3% | ||
| Q2 25 | 14.3% | 2.5% | ||
| Q1 25 | 14.3% | -44.5% | ||
| Q4 24 | 8.9% | 39.0% | ||
| Q3 24 | 24.1% | 17.0% | ||
| Q2 24 | 34.6% | -0.3% | ||
| Q1 24 | 27.1% | -37.1% |
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | 0.3% | ||
| Q2 25 | 6.1% | 0.6% | ||
| Q1 25 | 6.3% | 0.5% | ||
| Q4 24 | 6.7% | 6.0% | ||
| Q3 24 | 7.2% | 1.8% | ||
| Q2 24 | 3.3% | 1.4% | ||
| Q1 24 | 5.1% | 0.4% |
| Q4 25 | 1.35× | 1.70× | ||
| Q3 25 | 3.03× | 3.19× | ||
| Q2 25 | 1.15× | 0.48× | ||
| Q1 25 | 1.39× | -4.44× | ||
| Q4 24 | 0.76× | 5.30× | ||
| Q3 24 | 1.48× | 2.76× | ||
| Q2 24 | 1.82× | 0.28× | ||
| Q1 24 | 1.28× | -4.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
CRAI
Segment breakdown not available.
